文献速递外周动脉疾病

通过跨中心盲法同行评审识别因跛行行股动脉至腘动脉膨体聚四氟乙烯旁路移植术中可能可避免的病例

Identifying potentially avoidable femoral to popliteal expanded polytetrafluoroethylene bypass for claudication using cross-site blinded peer review.
PubMed 文献 · J Vasc Surg · 2022-09-13

本研究利用全州临床注册数据,由执业血管外科医生对139例因跛行行股动脉至腘动脉膨体聚四氟乙烯旁路移植术的匿名病例进行回顾性跨中心盲法评审,共完成325次评审。结果显示41%的评审认为不会推荐手术,38%认为手术不适当,主要原因为缺乏术前药物和生活方式治疗;

要点

  • 325次评审中,41%认为不会推荐旁路移植,38%认为手术不适当。
  • 手术不适当最常见原因为缺乏术前药物和生活方式治疗。

核心结论

  • 在该跨中心专家同行评审研究中,40%的下肢旁路移植术被认为为时过早,因而可能可避免,主要因术前缺乏药物和生活方式管理。

研究设计与样本

  • 执业血管外科医生对全州临床注册中因跛行行择期开放腹股沟下膨体聚四氟乙烯旁路移植术的病例进行回顾性临床评估。
  • 评审医生被随机分配10例来自139例匿名旁路手术样本的病例,依据专家意见和循证指南评估术前治疗(抗血小板、他汀、西洛他唑、运动、戒烟)的适当性。
  • 90天 episode 支付从1458例因跛行行择期开放下肢旁路移植术的相似队列中估算。

主要发现

  • 325次评审中,外科医生表示不会推荐旁路移植134次(41%),认为旁路移植不适当122次(38%)。
  • 不适当最常见原因为缺乏术前药物和生活方式治疗,在认为适当的评审中占63%,在认为不适当的评审中占39%(P < .001)。
  • 外科医生表示会推荐额外术前治疗在认为不适当的评审中占65%,在认为适当的评审中占35%(P < .001)。
  • 相似队列1458例因跛行行择期开放下肢旁路移植术患者的平均总 episode 支付为31,301美元 ± 21,219美元。
  • 外推至325次评审,不会推荐旁路移植的134次评审与潜在可避免的估算总支付4,194,334美元相关,认为不适当的122次评审与潜在可避免的估算总支付3,818,722美元相关。

关键数值与推荐

  • 术前治疗依据包括抗血小板、他汀、西洛他唑、运动、戒烟治疗。

临床怎么用

  • 作者认为该方法可告知外科医生的绩效反馈,以帮助临床实践与跛行治疗的循证推荐保持一致。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The surgical treatment of claudication can be associated with significant morbidity and costs. There are growing concerns that some patients proceed to interventions without first attempting evidence-based nonoperative management. We used a direct, cross-site, blinded expert review to evaluate the appropriateness of the surgical treatment of claudication. METHODS: We enlisted practicing vascular surgeons to perform retrospective clinical assessments of lower extremity bypass procedures in a statewide clinical registry. Cases were limited to elective, open, infrainguinal bypasses performed for claudication using prosthetic grafts. Reviewing surgeons were randomly assigned 10 cases from a sample of 139 anonymized bypass operations and instructed to evaluate procedural appropriateness based on their expert opinion and evidence-based guidelines for preoperative treatment, namely, antiplatelet, statin, cilostazol, exercise, and smoking cessation therapy as documented in the medical record. Ninety-day episode payments were estimated from a distinct but similar cohort of patients undergoing lower extremity bypass for claudication. RESULTS: Of 325 total reviews, surgeons stated they would not have recommended bypass in 134 reviews (41%) and deemed bypass inappropriate in 122 reviews (38%). The most common reason for inappropriateness was lack of preoperative medical and lifestyle therapy, which was present in 63% of reviews where bypass was deemed appropriate and 39% of reviews where bypass was deemed inappropriate (P < .001). Surgeons stated they would have recommended additional preoperative therapy in 65% of reviews where bypass was deemed inappropriate and 35% of reviews where bypass was deemed appropriate (P < .001). The mean total episode payments in a similar cohort of 1458 patients undergoing elective open lower extremity bypass for claudication were $31,301 ± $21,219. Extrapolating to the 325 reviews, the 134 reviews in which surgeons would not have recommended bypass were associated with potentially avoidable estimated total payments of $4,194,334, and the 122 reviews in which bypass was deemed inappropriate were associated with potentially avoidable estimated total payments of $3,818,722. CONCLUSIONS: In this cross-site expert peer review study, 40% of lower extremity bypasses were deemed premature and, therefore, potentially avoidable, primarily owing to a lack of medical and lifestyle management before surgery. Reviews deemed inappropriate were associated with approximately $4 million in potentially avoidable costs. This approach could inform performance feedback among surgeons to help align clinical practice with evidence-based recommendations for the treatment of claudication.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Howard R, Albright J, Fleckenstein R, et al. Identifying potentially avoidable femoral to popliteal expanded polytetrafluoroethylene bypass for claudication using cross-site blinded peer review. J Vasc Surg. 2022. PMID: 36113823. doi:10.1016/j.jvs.2022.09.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。